Gilead Sciences Acquires Tubulis for $3.15 Billion to Expand Oncology Portfolio

Gilead Sciences has acquired Tubulis for $3.15 billion, a strategic move aimed at expanding its oncology portfolio. This acquisition underscores Gilead's commitment to strengthening its presence in cancer treatment and research.